THE DOSE

your daily dose of Innovative, trending, and groundbreaking stories from across the cosmos.

AIsasIA 1/9/24 AIsasIA 1/9/24

Awakn Life Sciences Advances AWKN-P001 into Pivotal Phase III Trials

In a landmark step for addiction treatment, Awakn Life Sciences Corp. has received the green light to commence Phase III clinical trials for its pioneering treatment, AWKN-P001, targeting Severe Alcohol Use Disorder (SAUD).